Welcome to our dedicated page for Cabaletta Bio SEC filings (Ticker: CABA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cabaletta Bio, Inc. (Nasdaq: CABA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biotechnology company focused on targeted cell therapies for autoimmune diseases, Cabaletta Bio uses filings such as Forms 8-K, 10-Q and 10-K to report material events, financial results and key developments in its RESET™ clinical program for rese-cel (resecabtagene autoleucel).
Investors reviewing Cabaletta Bio’s filings can find details on quarterly and annual financial performance, including research and development and general and administrative expenses, as well as information on public offerings used to fund clinical and commercial readiness activities. Current reports on Form 8-K often furnish press releases that summarize clinical data from the RESET-Myositis™, RESET-SSc™, RESET-SLE™, RESET-MG™ and RESET-PV™ trials, describe regulatory interactions with the U.S. Food and Drug Administration, and outline registrational cohort designs for rese-cel in specific autoimmune indications.
Filings may also discuss regulatory designations granted to rese-cel, such as Regenerative Medicine Advanced Therapy and Fast Track designations, and PRIME access from the European Medicines Agency, along with updates on chemistry, manufacturing and controls activities and collaborations, including the use of Cellares’ automated Cell Shuttle™ and Cell Q™ platforms for clinical manufacturing and quality control testing. These disclosures help readers understand how Cabaletta Bio is preparing for potential Biologics License Application submissions and future commercialization.
On Stock Titan, Cabaletta Bio’s SEC filings are updated as new documents are posted to EDGAR, and AI-powered summaries can help explain the contents of lengthy reports, such as annual reports on Form 10-K or quarterly reports on Form 10-Q. Users can also monitor Form 8-K filings for material clinical, regulatory or financing events related to rese-cel and the broader CABA™ platform. This page is a resource for analyzing Cabaletta Bio’s regulatory history, financial condition and key milestones in its autoimmune-focused cell therapy programs.
Cabaletta Bio, Inc. updated its corporate presentation highlighting progress of rese-cel (CABA-201), a CD19 CAR T cell therapy being developed for multiple autoimmune diseases. The company outlines Phase 1/2 data in myositis, systemic lupus erythematosus (SLE), systemic sclerosis (SSc), myasthenia gravis (MG) and pemphigus vulgaris (PV).
Early results show immunomodulator-free clinical responses in dermatomyositis and antisynthetase syndrome using a single weight-based dose, with patients achieving meaningful Total Improvement Score responses while tapering or stopping steroids. In SLE, SSc and MG, patients with active, refractory disease showed improvements in validated disease scores and reductions in autoantibodies after discontinuing multiple prior therapies.
The presentation emphasizes a safety profile that supports outpatient administration, with low rates and delayed onset of cytokine release syndrome and rare neurotoxicity across the first 40 rese-cel–treated autoimmune patients. Cabaletta also details an automation strategy with Cellares and exploration of no-preconditioning regimens aimed at scaling manufacturing, reducing cost of goods and expanding access across high-need autoimmune indications.
Cabaletta Bio, Inc. is soliciting proxies for its virtual 2026 Annual Meeting to be held June 9, 2026, with a record date of April 20, 2026. The board is asking shareholders to elect two Class I directors, ratify Ernst & Young as auditor, approve an amendment to the 2019 Stock Option and Incentive Plan to include pre-funded warrants in its evergreen calculation, and approve a charter amendment to increase authorized common shares from 300,000,000 to 600,000,000. The proxy materials and the 2025 Annual Report will be available at the company web portal and the SEC site. Voting mechanics, broker vote effects, and quorum rules are described in the proxy statement.
Cabaletta Bio presents a late clinical-stage pipeline built around rese-cel, a CD19 CAR T therapy aimed at delivering one-time, potentially durable treatment for multiple autoimmune diseases. The company is running parallel Phase 1/2 RESET trials in SLE, myositis, systemic sclerosis, generalized myasthenia gravis and pemphigus vulgaris, and has already initiated a registrational DM/ASyS cohort in myositis with a planned BLA submission in 2027.
Rese-cel has received multiple FDA designations, including Fast Track, Orphan Drug, Rare Pediatric Disease and RMAT across several indications, and Cabaletta is building a multi-partner manufacturing network with Oxford Biomedica, Minaris, Lonza and Cellares to scale supply, including automated production. As of June 30, 2025, non-affiliate market value was about $137 million, with 111,322,671 common shares outstanding as of March 19, 2026. Management discloses substantial doubt about the company’s ability to continue as a going concern beyond its current cash runway into the fourth quarter of 2026 without additional funding.
Cabaletta Bio reported fourth quarter and full year 2025 results and highlighted rapid progress of its CD19 CAR-T candidate rese-cel across multiple autoimmune diseases. R&D expenses rose to $36.2M for the quarter and $142.7M for the year, reflecting expansion of the RESET clinical program. The company ended December 31, 2025 with $133.6M in cash, cash equivalents and short-term investments and subsequently raised an additional $30.0M via ATM sales and warrant exercises. Management believes this cash position can fund the operating plan into the fourth quarter of 2026.
Cabaletta outlined a 17-patient single-arm registrational myositis cohort targeting a potential 2027 BLA submission, reported favorable early safety data in the first 40 rese-cel patients with preconditioning, and detailed an expanding Phase 1/2 dataset in systemic lupus erythematosus, systemic sclerosis and myasthenia gravis with complete Phase 1/2 data expected in the first half of 2026. The company is also advancing a no-preconditioning strategy, automated manufacturing with Cellares’ Cell Shuttle and plans multiple readouts in 2026 that are intended to support FDA discussions on registrational designs across indications.
Cabaletta Bio, Inc. reported that Chief Business Officer Arun Das received a grant of stock options. The award covers 175,000 options to buy Cabaletta Bio common stock at an exercise price of $0.00 per share, representing a compensatory equity grant rather than a market purchase.
According to the vesting terms, 25% of the shares underlying this option vest and become exercisable on March 1, 2027. The remaining options vest in twelve substantially equal quarterly installments after that date, as long as he continues in service through each vesting date.
Cabaletta Bio, Inc. reported that its General Counsel, Gerard Michael, received a grant of stock options covering 175,000 shares of common stock. The options were awarded at an exercise price of $0.00 per share, reflecting a compensatory equity award rather than an open-market purchase.
According to the vesting terms, 25% of the shares subject to the option will vest and become exercisable on March 1, 2027. The remaining 75% will vest in twelve substantially equal quarterly installments after that date, conditioned on his continued service with the company on each vesting date.
Cabaletta Bio, Inc. reported that President, Science & Tech. Gwendolyn Binder acquired a grant of 225,000 stock options on March 2, 2026. These options have a stated price of $0.00 per share and represent rights to buy Cabaletta Bio common stock in the future.
According to the vesting terms, 25% of the shares underlying this option vest and become exercisable on March 1, 2027, with the remaining options vesting in twelve substantially equal quarterly installments thereafter, contingent on her continued service on each vesting date.
Cabaletta Bio, Inc. reported that Chief Medical Officer David J. Chang acquired a new stock option award covering 225,000 shares of company stock. This option was granted as a derivative security and represents his total option holdings after the reported transaction.
According to the vesting terms, 25% of the shares underlying this option will vest and become exercisable on March 1, 2027. The remaining shares will vest in twelve substantially equal quarterly installments after that date, conditioned on his continued service with the company on each vesting date.
Nichtberger Steven reported acquisition or exercise transactions in this Form 4 filing.
Cabaletta Bio reported that President and CEO Steven Nichtberger received a grant of stock options covering 674,000 shares of the company’s common stock. The options were awarded at no cost to him, increasing his directly held option position to 674,000 options after the grant.
According to the vesting terms, 25% of the shares underlying this option will vest and become exercisable on March 1, 2027. The remaining 75% will vest in twelve substantially equal quarterly installments after that date, conditioned on his continued service with the company on each vesting date.
Cabaletta Bio, Inc. reported that its Chief Financial Officer, Anup Marda, received a grant of stock options covering 225,000 shares of common stock. The options were acquired as a grant, with 25% scheduled to vest and become exercisable on March 1, 2027, and the remaining 75% vesting in twelve substantially equal quarterly installments thereafter, conditioned on his continued service with the company on each vesting date.